11.02
-0.84 (-7.08%)
-0.84 (-7.08%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Eiger BioPharmaceuticals Inc | EIGR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.84 | -7.08% | 11.02 | 18:42:18 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 11.84 | 10.98 | 12.071 | 11.02 | 11.86 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 10.79 | 11.75 | 0.96 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,453 | 332,525 | $ 11.48 | $ 3,816,528 | 675,921 | 4.55 - 15.12 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:03:30 | 15 | $ 11.02 | USD |
Eiger BioPharmaceuticals Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 358.50M | 32.53M | 31.97M | $ - | $ - | -3.09 | -4.70 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 1.10% |
Eiger BioPharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EIGR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 11.68 | 12.1699 | 10.98 | 11.59 | 370,555 | -0.66 | -5.65% |
| 1 Month | 10.03 | 12.75 | 9.41 | 11.29 | 560,160 | 0.99 | 9.87% |
| 3 Months | 10.00 | 12.75 | 8.58 | 10.21 | 578,009 | 1.02 | 10.2% |
| 6 Months | 9.77 | 12.75 | 7.57 | 10.19 | 533,022 | 1.25 | 12.79% |
| 1 Year | 14.59 | 15.12 | 4.55 | 10.08 | 442,219 | -3.57 | -24.47% |
| 3 Years | 9.60 | 18.00 | 4.55 | 10.65 | 248,665 | 1.42 | 14.79% |
| 5 Years | 17.40 | 23.10 | 4.55 | 10.72 | 170,786 | -6.38 | -36.67% |
Eiger BioPharmaceuticals Description
| Eiger BioPharmaceuticals Inc is a late-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3. |
